Advanced Malignant Tumor
Conditions
Brief summary
This is an open-label, multicenter, Phase 1, ascending dose escalation study of QL1706 in subjects with advanced malignant tumor. The study will be conducted in 2 parts. Part 1 of the study will be a dose escalation evaluation to determine the maximum tolerated dose (MTD) and to establish a recommended Phase 2 dose (RP2D) of QL1706. This study purpose is to describe the safety and tolerability, to assess Pharmacokinetics (PK) and immunogenicity, and to preliminarily assess the anti-tumor activity of QL1706 in subjects with advanced malignant tumor. Part 2 of the study will further characterize the PK parameters for QL1706 in subjects with advanced malignant tumor.
Detailed description
The study was divided into screening/baseline, treatment and follow-up periods. Safety monitoring will be conducted throughout the study period. DLT will be determined 21 days (1 cycle) after the first administration of QL1706 based on the occurrence of AE during the treatment period.
Interventions
BIOLOGICALQL1706
QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects aged 18 years or older. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 3. Life expectancy of ≥3 months. 4. The functional level of important organs must meet the requirements before the first dose of study drug. 5. Male and female patients able to have children must agree to use highly effective method of contraception throughout the study and for at least 180 days after last dose.Female subjects who are not pregnant or breastfeeding. 6. Patients with pathological diagnosis of advanced/metastatic malignant tumor have progressed disease on standard therapy or for which no effective therapy is avalizble.
Exclusion criteria
1. Active or prior documented autoimmune disease. Subjects who have stable hypothyroidism with hormone replacement ,childhood atopy or asthma, vitiligo, alopecia, , or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. 2. Grade 3 or Grade 4 irAEs related to prior cancer immunotherapy. 3. Known symptomatic brain metastases, leptomeningeal disease or spinal cord compression. 4. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment on decision of investigator. . 5. Any condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days before first dose of study drug. Corticosteroids for topical use, nasal spray, and inhaled steroids are allowed. Systemic corticosteroids for prophylaxis of contrast allergy are permitted. 6. Systemic anti-cancer treatment. This includes radiotherapy ,small molecule targeted therapy\<2 weeks before the first dose of study drug, ≤4 weeks for chemotherapy，monoclonal antibody;≤8 weeks for cell-based therapy or anti-tumor vaccine. 7. Major surgery within 28 days before the first dose of study drug and not recovered fully from any complications from surgery. 8. Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug. 9. Subjects with the history of organ transplant or allogeneic hematopoietic stem cells transpalnt. 10. Positive for Human immunodeficiency virus（HIV）or Hepatitis B ,active Hepatitis C. 11. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability | 1 Cycles (21 days) | Safety and tolerability, as defined by the rate of treatment-related adverse events as assessed by NCI CTCAE v5.0. |
Countries
China
Outcome results
None listed